Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(2 years from now) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
Signifor is owned by Recordati Rare.
Signifor contains Pasireotide Diaspartate.
Signifor has a total of 2 drug patents out of which 0 drug patents have expired.
Signifor was authorised for market use on 14 December, 2012.
Signifor is available in solution;subcutaneous dosage forms.
The generics of Signifor are possible to be released after 14 December, 2026.
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
SIGNIFOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic